Balance Sheet
Cash Flow Statement
Asset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in IntangiblesChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesSales of Property, Plant and EquipmentShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

IGC Pharma (IGC) Net Cash Flow (2016 - 2025)

Historic Net Cash Flow for Pharma (IGC) over the last 17 years, with Q3 2025 value amounting to $646000.0.

  • Pharma's Net Cash Flow rose 34194.76% to $646000.0 in Q3 2025 from the same period last year, while for Sep 2025 it was -$473000.0, marking a year-over-year increase of 6791.04%. This contributed to the annual value of -$786000.0 for FY2025, which is 6054.22% up from last year.
  • According to the latest figures from Q3 2025, Pharma's Net Cash Flow is $646000.0, which was up 34194.76% from $24000.0 recorded in Q2 2025.
  • In the past 5 years, Pharma's Net Cash Flow registered a high of $13.6 million during Q1 2021, and its lowest value of -$2.5 million during Q4 2021.
  • In the last 5 years, Pharma's Net Cash Flow had a median value of -$1.1 million in 2024 and averaged $12052.6.
  • The largest annual percentage gain for Pharma's Net Cash Flow in the last 5 years was 58313.77% (2021), contrasted with its biggest fall of 119424.08% (2021).
  • Pharma's Net Cash Flow (Quarter) stood at -$2.5 million in 2021, then skyrocketed by 32.65% to -$1.7 million in 2022, then increased by 0.96% to -$1.6 million in 2023, then surged by 34.75% to -$1.1 million in 2024, then soared by 160.04% to $646000.0 in 2025.
  • Its Net Cash Flow was $646000.0 in Q3 2025, compared to $24000.0 in Q2 2025 and -$67000.0 in Q1 2025.